JMP Securities has recently reduced Progyny Inc (PGNY) stock to Mkt Perform rating, as announced on September 19, 2024, according to Finviz. Earlier, on August 7, 2024, Leerink Partners had reduced the stock from a Outperform to Market Perform, setting a price target of $25 for PGNY stock. Canaccord Genuity also reduced Hold rating with a price target of $24. Additionally, BTIG Research reduced Neutral rating on August 7, 2024. JMP Securities analysts, in their report published on July 16, 2024, also initiated Mkt Outperform rating for Progyny Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Progyny Inc (PGNY) Stock Trading Recap
On Tuesday, Progyny Inc (PGNY) stock saw a decline, ending the day at $16.18 which represents a decrease of $-0.58 or -3.46% from the prior close of $16.76. The stock opened at $16.89 and touched a low of $16.13 during the day, reaching a high of $16.89. The volume of shares traded was 1.30 million falling short of the average volume of 2.04 million.
PGNY Stock Performance and Moving Averages
In recent trading, Progyny Inc (PGNY) stock price has shown some volatility, fluctuating -5.66% over the last five trades and -31.12% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -54.64%, and it has plunged by -42.89% in the previous three months. Currently, PGNY is trading at -22.80%, -28.88%, and -47.65% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, PGNY, a Healthcare sector stock, is trading -61.55% below its 52-week high but remains 16.15% above its 52-week low. The Average True Range (ATR) (14 days) of 1.19 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Progyny Inc’s Profitability and Valuation Ratios
Progyny Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 6.28% and a profit margin of 5.54%, with a gross margin of -54.64%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Progyny Inc’s market capitalization stands at $1.46 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The stock’s price-to-earnings (P/E) ratio is 25.81, assessing the company’s valuation relative to its earnings. The forward P/E ratio, which uses projected earnings for the next financial year, is 22.73. Additionally, the Price-to-Sales Ratio is 1.29, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 3.22, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 15.29% of Progyny Inc (PGNY)’s shares, while financial institutions hold 91.92%.
Notable insider trades include Sturmer Michael E, PRESIDENT at Progyny Inc (PGNY), who sold 9030 shares on Jul 16 ’24, at $30 each, totaling $0.27 million. On May 01 ’24, Sturmer Michael E, PRESIDENT, sold 4515 shares for $31.95 each, amounting to $0.14 million. Additionally, on Apr 01 ’24, Sturmer Michael E sold 6395 shares at $37.6 each, generating $0.24 million.
